SRC and neoplasm: This suggests that the NCIH747 cell line could respond to tyrosine kinase inhibitors (TKIs) prescribed by Beyondcell for these tumour types such as EGFRi and also to inhibitors to target members from MAPK pathway (MEK and SRC).